Development of liposomal ciprofloxacin to treat lung infections

Pharmaceutics

Volumn 8, Issue 1, 2016, Pages

  Cipolla, David ^a   Blanchard, Jim ^a   Gonda, Igor ^a  

^a ARADIGM CORPORATION   (United States)

Author keywords

Bronchiectasis; Ciprofloxacin; Cystic fibrosis; Formulation; Inhalation delivery; Liposomes; Lung infection; Non tuberculous mycobacteria

Indexed keywords

CIPROFLOXACIN; LIPOSOMAL CIPROFLOXACIN; UNCLASSIFIED DRUG;

AEROSOL; ANTIBIOTIC THERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG STABILITY; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG INFECTION; NEBULIZATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; Q FEVER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TULAREMIA;

EID: 84960078694     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics8010006     Document Type: Review

References (83)

1. Cipolla, D.; Chan, H.-K. Inhaled Antibiotics to Treat Lung Infection. Pharm. Patent Analyst. 2013, 2, 647–663. [CrossRef][PubMed]
2. Weers, J. Inhaled antimicrobial therapy - barriers to effective treatment. Adv. Drug Deliv. Rev. 2015, 85, 24–43. [CrossRef][PubMed]
3. Wright, D.H.; Brown, G.H.; Peterson, M.L.; Rotschafer, J.C. Application of fluoroquinolone pharmacodynamics. J Antimicrob. Chemo. 2000, 46, 669–683. [CrossRef]
4. Wargo, K.A.; Edwards, J.D. Aminoglycoside-Induced Nephrotoxicity. J. Pharm. Pract. 2014, 27, 573–577. [CrossRef][PubMed]
5. Fink, M.P.; Snydman, D.R.; Niederman, M.S.; Leeper, K.V., Jr.; Johnson, R.H.; Heard, S.O.; Wunderink, R.G.; Caldwell, J.W.; Schentag, J.J.; Siami, G.A. et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob. Agents Chemother. 1994, 38, 547–557. [CrossRef][PubMed]
6. Peloquin, C.A.; Cumbo, T.J.; Nix, D.E.; Sands, M.F.; Schentag, J.J. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch. Intern Med. 1989, 149, 2269–2273. [CrossRef][PubMed]
7. Firsov, A.A.; Vostrov, S.N.; Shevchenko, A.A.; Zinner, S.H.; Cornaglia, G.; Portnoy, Y.A. MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model. Antimicrob. Agents Chemother. 1998, 42, 2848–2852. [PubMed]
8. Forrest, A.; Nix, D.E.; Ballow, C.H.; Goss, T.F.; Birmingham, M.C.; Schentag, J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 1993, 37, 1073–1081. [CrossRef][PubMed]
9. Bruinenberg, P.; Blanchard, J.D.; Cipolla, D.C.; Dayton, F.; Mudumba, S.; Gonda, I. Inhaled liposomal ciprofloxacin: Once a day management of respiratory infections. In Proceedings of Respiratory Drug Delivery 2010; Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Farr, S.J., Young, P.M., Eds.; Davis Healthcare International Publishing: River Grove, IL, USA, 2010; pp. 73–81.
10. Bruinenberg, P.; Serisier, D.; Cipolla, D.; Blanchard, J. Safety, Tolerability, Pharmacokinetics and Antimicrobial Activity of Inhaled Liposomal Ciprofloxacin Formulations in Humans. Pediatr. Pulmonol. 2010, 45, 354.
11. Rotrovato, C.A.; Deeter, R.G. Respiratory Tract Penetration of Quinolone Antimicrobials: A Case in Study. Pharmacotherapy 1991, 11, 38–49.
12. Moskowitz, S.M.; Foster, J.M.; Emerson, J.; Burns, J.L. Clinically Feasible Biofilm Susceptibility Assay for Isolates of Pseudomonas aeruginosa from Patients with Cystic Fibrosis. J. Clin. Microbiol. 2004, 42, 1915–1922. [CrossRef][PubMed]
13. Chalmers, J.D.; Aliberti, S.; Blasi, F. Management of bronchiectasis in adults. Eur. Respir. J. 2015, 45, 1446–1462. [CrossRef][PubMed]
14. Parameswaran, I.; Sethi, S. Pseudomonas infection in chronic obstructive pulmonary disease. Future Microbiol. 2012, 7, 1129–1132. [CrossRef][PubMed]
15. Finch, S.; McDonnell, M.J.; Abo-Leyah, H.; Aliberti, S.; Chalmers, J.D. A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis. Ann. Am. Thorac. Soc. 2015, 2, 1602–1611.
16. Bilton, D.; Henig, N.; Morrissey, B.; Gotfried, M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006, 130, 1503–1510. [CrossRef][PubMed]
17. Barker, A.F.; O’Donnell, A.E.; Flume, P.; Thompson, P.J.; Ruzi, J.D.; de Gracia, J.; Boersma, W.G.; De Soyza, A.; Shao, L.; Zhang, J. et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): Two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir. Med. 2014, 2, 738–749. [CrossRef]
18. Haworth, C.S.; Foweraker, J.E.; Wilkinson, P.; Kenyon, R.F.; Bilton, D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 2014, 189, 975–982. [CrossRef][PubMed]
19. Grimwood, K.; Bell, S.C.; Chang, A.B. Antimicrobial treatment of non-cystic fibrosis bronchiectasis. Expert Rev. Anti-Infect. Ther. 2014, 12, 1277–1296. [CrossRef][PubMed]
20. Chalmers, J.D.; Smith, M.P.; McHugh, B.J.; Doherty, C.; Govan, J.R.; Hill, A.T. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2012, 186, 657–665. [CrossRef][PubMed]
21. Serisier, D.J.; Bilton, D.; De Soyza, A.; Thompson, P.J.; Kolbe, J.; Greville, H.W.; Cipolla, D.; Bruinenberg, P.; Gonda, I. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): A randomised, double-blind, placebo-controlled trial. Thorax 2013, 68, 812–817. [CrossRef][PubMed]
22. Adjemian, J.; Olivier, K.N.; Seitz, A.E.; Holland, S.M.; Prevots, D.R. Prevalence of nontuberculosis mycobacterial lung disease in US Medicare beneficiaries. Am. J. Respir. Crit. Care Med. 2012, 185, 881–886. [CrossRef][PubMed]
23. Olivier, K.N.; Gupta, R.; Daley, C.L.; Winthrop, K.L.; Ruoss, S.; Addrizzo-Harris, D.J.; Flume, P.; Dorgan, D.; Salathe, M.A.; Brown-Elliott, B.A. et al. A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation in Patients with Recalcitrant Nontuberculous Mycobacterial Lung Disease. In Presented at ATS Conference, San Diego, CA, USA, 20 May 2014; #50985. Insmed Publications & Presentations. Available online: http://www.insmed.com/publications-presentations/ (accessed on 31 December 2015).
24. Ruoss, S.; Eagle, G.; McGinnis, J.P., II; Micioni, L.; Daley, C.L.; Winthrop, K.L.; Addrizzo-Harris, D.J.; Flume, P.; Dorgan, D.; Salathe, M. et al. Analysis of Functional Exercise Capacity (via the Six-Minute Walk Test [6MWT]) and Negative Sputum Culture for Nontuberculous Mycobacteria (NTM) in Patients With NTM Lung Infection Refractory to Guideline-Based Therapy TreatedWith Liposomal Amikacin for Inhalation (LAI). In Presented at ATS Conference, Denver, CO, USA, 20 May 2015; #612. Insmed Publications & Presentations. Available online: http://www.insmed.com/publications-presentations/ (accessed on 31 December 2015).
25. Rose, S.J.; Neville, M.E.; Gupta, R.; Bermudez, L.E. Delivery of Aerosolized Liposomal Amikacin as a Novel Approach for the Treatment of Nontuberculous Mycobacteria in an Experimental Model of Pulmonary Infection. PLoS ONE 2014, 9, e108703. [CrossRef][PubMed]
26. Blanchard, J.; Danelishvili, L.; Gonda, I.; Bermudez, L. Liposomal Ciprofloxacin Preparation is Active against Mycobacterium Avium Subsp Hominissuis and Mycobacterium Abscessus in Macrophages and in Biofilm. In Presented at ATS Conference, San Diego, CA, USA, 20 May 2014; #57372. Available online: http://investor.aradigm.com/releasedetail.cfm?ReleaseID=840192 (accessed on 31 December 2015).
27. Blanchard, J.; Danelishvili, L.; Gonda, I.; Bermudez, L. Treatment of lung infection caused by Mycobacterium abscessus in Beige mice with pulmonary delivery of liposomally encapsulated ciprofloxacin is associated with significant reduction of bacterial load. In Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2015; Poster #B-536. Available online: http://investor.aradigm.com/releasedetail.cfm?ReleaseID=930955 (accessed on 31 December 2015).
28. Bermudez, L.E.; Blanchard, J.D.; Hauck, L.; Gonda, I. Treatment of Mycobacterium avium subsp hominissuis (MAH) lung infection with liposome-encapsulated ciprofloxacin resulted in significant decrease in bacterial load in the lung. Am J Respir Crit Care Med. 2015, 191, A6293. Available online: http://investor.aradigm.com/releasedetail.cfm?releaseid=912485 (accessed on 31 December 2015).
29. Meers, P.; Neville, M.; Malinin, V.; Scotto, A.W.; Sardaryan, G.; Kurumunda, R.; Mackinson, C.; James, G.; Fisher, S.; Perkins, W.R. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemo. 2008, 61, 859–868. [CrossRef][PubMed]
30. Cipolla, D.; Gonda, I.; Chan, H.-K. Liposomal Formulations for Inhalation. Ther. Deliv. 2013, 4, 1047–1072. [CrossRef][PubMed]
31. Cipolla, D.; Shekunov, B.; Blanchard, J.; Hickey, T. Lipid-based carriers for pulmonary products: Preclinical development and case studies in Humans. Adv. Drug Deliv. Rev. 2014, 75, 53–80. [CrossRef][PubMed]
32. Cipolla, D.; Redelmeier, T.; Eastman, S.; Bruinenberg, P.; Gonda, I. Liposomes, Niosomes and Proniosomes—A Critical Update of Their (Commercial) Development as Inhaled Products. In Proceedings of Respiratory Drug Delivery Europe 2011; Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Farr, S.J., Young, P.M., Eds.; Davis Healthcare International Publishing: River Grove, IL, USA, 2011; pp. 41–54.
33. Yim, D.; Blanchard, J.D.; Mudumba, S.; Eastman, S.; Manda, K.; Redelmeier, T.; Farr, S. The Development of Inhaled Liposome-Encapsulated Ciprofloxacin to Treat Cystic Fibrosis. In Proceedings of Respiratory Drug Delivery 2006; Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Farr, S.J., Eds.; Davis Healthcare International Publishing: River Grove, IL, USA, 2006; pp. 425–428.
34. Webb, M.S.; Boman, N.L.; Wiseman, D.J.; Saxon, D.; Sutton, K.; Wong, K.F.; Logan, P.; Hope, M.J. Antibacterial Efficacy Against an in Vivo Salmonella Typhimurium Infection Model and Pharmacokinetics of a Liposomal Ciprofloxacin Formulation. Antimicrob. Agents Chemother. 1998, 42, 45–52. [PubMed]
35. Barriere, S.L.; Kaatz, G.W.; Schaberg, D.R.; Fekety, R. Altered pharmacologic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits. Antimicrob. Agents Chemother. 1987, 31, 1075–1078. [CrossRef][PubMed]
36. Blanchard, J. Pulmonary Drug Delivery as a First Response to Bioterrorism. In Proceedings of Respiratory Drug Delivery 2006; Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Farr, S.J., Eds.; Davis Healthcare International Publishing: River Grove, IL, USA, 2006; pp. 73–82.
37. Wong, J.P.; Yang, H.; Blasetti, K.L.; Schnell, G.; Conley, J.; Schofield, L.N. Liposome Delivery of Ciprofloxacin against Intracellular Francisella tularensis Infection. J. Control. Release 2003, 92, 265–273. [CrossRef]
38. Ong, H.X.; Traini, D.; Cipolla, D.; Gonda, I.; Bebawy, M.; Agus, H.; Young, P.Y. Liposomal Nanoparticles Control the Uptake of Ciprofloxacin Across Respiratory Epithelia. Pharm. Res. 2012, 29, 3335–3346. [CrossRef][PubMed]
39. Ong, H.X.; Benaouda, F.; Traini, D.; Cipolla, D.; Gonda, I.; Forbes, B.; Young, P.M. In Vitro and ex Vivo Methods Predict the Enhanced Lung Residence Time of Liposomal Ciprofloxacin Formulations for Nebulisation. Eur. J. Pharm. Biopharm. 2014, 86, 83–89. [CrossRef][PubMed]
40. Li, Z.; Zhang, Y.; Wurtz, W.; Lee, J.K.; Malinin, V.S.; Durwas-Krishnan, S.; Meers, P.; Perkins, W.R. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J. Aerosol. Med. Pulm. Drug Deliv. 2008, 21, 245–254. [CrossRef][PubMed]
41. Cipolla, D.C.; Dayton, F.; Fulzele, S.; Gabatan, E.; Mudumba, S.; Yim, D.; Wu, H.; Zwolinski, R. Inhaled Liposomal Ciprofloxacin: In Vitro Properties and Aerosol Performance. In Proceedings of Respiratory Drug Delivery 2010; Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Farr, S.J., Young, P.M., Eds.; Davis Healthcare International Publishing: River Grove, IL, USA, 2010; pp. 409–414.
42. Cipolla, D.; Wu, H.; Chan, J.; Chan, H.-K.; Gonda, I. Liposomal Ciprofloxacin for Inhalation Retains Integrity Following Nebulization. In Proceedings of Respiratory Drug Delivery Europe 2013; Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Farr, S.J., Young, P.M., Eds.; Davis Healthcare International Publishing: River Grove, IL, USA, 2013; pp. 237–242.
43. Cipolla, D.; Wu, H.; Eastman, S.; Redelmeier, T.; Gonda, I.; Chan, H.-K. Development and characterization of an in vitro release assay for liposomal ciprofloxacin for inhalation. J. Pharm. Sci. 2014, 103, 314–327. [CrossRef]
44. Finlay, W.H.; Wong, J.P. Regional lung deposition of nebulized liposome-encapsulated ciprofloxacin. Int. J. Pharm. 1998, 167, 121–127. [CrossRef]
45. Grit, M.; Crommelin, D.J.A. Chemical stability of liposomes: Implications for their physical stability. Chem. Phys. Lipids. 1993, 64, 3–18. [CrossRef]
46. Cipolla, D.; Gonda, I.; Serisier, D.; Bruinenberg, P. Dual Release Ciprofloxacin for Inhalation (DRCFI) Improves Time to First Exacerbation in Bronchiectasis. J. Aerosol. Med. Pulm. Drug Deliv. 2011, 24, A-27.
47. Almgren, M.; Edwards, K.; Karlsson, G. Cryo transmission electron microscopy of liposomes and related structures. Colloids Surf. A 2000, 174, 3–21. [CrossRef]
48. FDA. Draft Guidance for Industry. Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation October 2015. Available online: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm 070570.pdf (accessed on 18 February 2016).
49. ICH Quality Guidelines. Available online: http://www.ich.org/products/guidelines/quality/article/ quality-guidelines.html.
50. Hamblin, K.A.; Armstrong, S.J.; Barnes, K.B.; Davies, C.; Wong, J.P.; Blanchard, J.D.; Harding, S.V.; Simpson, A.J.; Atkins, H.S. Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4. Antimicrob. Agents Chemother. 2014, 58, 3053–3059. [CrossRef][PubMed]
51. Hamblin, K.A.; Blanchard, J.D.; Davis, C.; Harding, S.V.; Simpson, A.J.H. Efficacy of inhaled liposome-encapsulated ciprofloxacin against Yersinia pestis. J. Aer. Med. Pulm. Drug Deliv. 2013, 26, A-16.
52. Norville, I.H.; Hatch, G.J.; Bewley, K.R.; Atkinson, D.J.; Hamblin, K.A.; Blanchard, J.D.; Armstrong, S.J.; Pitman, J.K.; Rayner, E.; Hall, G. et al. Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever. Antimicrob. Agents Chemother. 2014, 58, 5510–5518. [CrossRef][PubMed]
53. Sheth, V.R.; van Heeckeren, R.C.; Wilson, A.G.; van Heeckeren, A.M.; Pagel, M.D. Monitoring infection and inflammation in murine models of cystic fibrosis with magnetic resonance imaging. J. Magn. Reson. Imaging. 2008, 28, 527–532. [CrossRef][PubMed]
54. Dennis, D.T.; Inglesby, T.V.; Henderson, D.A.; Bartlett, J.G.; Ascher, M.S.; Eitzen, E.; Fine, A.D.; Friedlander, A.M.; Hauer, J.; Layton, M. et al. Working Group on Civilian Biodefense. Tularemia as a biological weapon: Medical and public health management. JAMA 2001, 285, 2763–2773. [CrossRef][PubMed]
55. Perez-Castrillon, J.L.; Bachiller-Luque, P.; Martin-Luquero, M.; Mena-Martin, F.J.; Herreros, V. Tularemia epidemic in northwestern Spain: Clinical description and therapeutic response. Clin. Infect. Dis. 2001, 33, 573–576. [CrossRef][PubMed]
56. Chocarro, A.; Gonzalez, A.; Garcia, I. Treatment of tularemia with ciprofloxacin. Clin. Infect. Dis. 2000, 31, 623. [CrossRef][PubMed]
57. Hepburn, M.J.; Simpson, A.J.H. Tularemia: Current diagnosis and treatment options. Expert Rev. Anti-Infect. Ther. 2008, 6, 231–240. [CrossRef][PubMed]
58. Steward, J.; Piercy, T.; Lever, M.S.; Simpson, A.J.H.; Brooks, T.J.G. Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin. Int. J. Antimicrob. Agents. 2006, 27, 439–443. [CrossRef][PubMed]
59. Conley, J.; Yang, H.; Wilson, T.; Blasetti, K.; Di Ninno, V.; Schnell, G.; Wong, J.P. Aerosol delivery of liposome-encapsulated ciprofloxacin: Aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob. Agents Chemother. 1997, 41, 1288–1292. [PubMed]
60. Di Ninno, V.L.; Cherwanogrodzky, J.W.; Wong, J.P. Liposome-encapsulated ciprofloxacin is effective in the protection and treatment of BALB/c mice against Francisella tularensis. J. Infect. Dis. 1993, 168, 793–794. [CrossRef][PubMed]
61. Hamblin, K.A.; Wong, J.P.; Blanchard, J.D.; Atkins, H.S. The Potential of Liposome-Encapsulated Ciprofloxacin as a Tularemia Therapy. Front. Cell Infect. Microbiol. 2014, 4, 79. [CrossRef][PubMed]
62. Brain, J.D.; Knudson, D.E.; Sorokin, S.P.; Davis, M.A. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ. Res. 1976, 11, 13–33. [CrossRef]
63. FDA. Draft Guidance for Industry. Animal models—Essential elements to address efficacy under the Animal Rule. Available online: http://www.fda.gov/downloads/drugs/guidancecompliance regulatoryinformation/guidances/ucm399217.pdf (accessed on 18 February 2016).
64. Maurin, M.; Raoult, D.Q. Fever. Clin Microbiol Rev. 1999, 12, 518–553. [PubMed]
65. Rolain, J.M.; Boulos, A.; Mallet, M.N.; Raoult, D. Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis. Antimicrob. Agents Chemother. 2005, 49, 2673–2676. [CrossRef][PubMed]
66. Fenollar, F.; Fournier, P.E.; Carrieri, M.P.; Habib, G.; Messana, T.; Raoult, D. Risks factors and prevention of Q fever endocarditis. Clin. Infect. Dis. 2001, 33, 312–316. [CrossRef][PubMed]
67. Anderson, A.; Bijlmer, H.; Fournier, P.E.; Graves, S.; Hartzell, J.; Kersh, G.J.; Limonard, G.; Marrie, T.J.; Massung, R.F.; McQuiston, J.H. et al. Diagnosis and management of Q fever–United States, 2013: Recommendations from CDC and the Q Fever Working Group. MMWR Recomm. Rep. 2013, 62(RR-03), 1–30. [PubMed]
68. CDC Q fever. Available online: http://www.cdc.gov/qfever/index.html (accessed on 18 February 2016).
69. Raoult, D.; Houpikian, P.; Dupont, H.; Riss, J.; Arditi-Djiane, J.J.; Brouqui, P. Treatment of Q fever endocarditis: Comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch. Intern. Med. 1999, 159, 167–173. [CrossRef][PubMed]
70. Maurin, M.; Benoliel, A.M.; Bongrand, P.; Raoult, D. Phagolysosomal alkalinization and the bactericidal effect of antibiotics: the Coxiella burnetii paradigm. J Infect Dis. 1992, 166, 1097–1102. [CrossRef][PubMed]
71. Rouli, L.; Rolain, J.M.; El Filali, A.; Robert, C.; Raoult, D. Genome sequence of Coxiella burnetii 109, a doxycycline-resistant clinical isolate. J. Bacteriol. 2012, 194, 6939. [CrossRef][PubMed]
72. Gikas, A.; Spyridaki, I.; Psaroulaki, A.; Kofterithis, D.; Tselentis, Y. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. Antimicrob. Agents Chemother. 1998, 42, 2747–2748. [PubMed]
73. Rubin, B.K. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J. Aer. Med. Pulm. Drug Deliv. 2008, 21, 71–76. [CrossRef][PubMed]
74. Darweesh, R.S.; Sakagami, M. In Vitro Inhibitory Activities of Liposomal Ciprofloxacin Against Lipopolysaccharide (LPS)-Induced IL-8 Release from the Calu-3 Cells. In Proceedings of Respiratory Drug Delivery 2014; Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Farr, S.J., Young, P.M., Eds.; Davis Healthcare International Publishing: River Grove, IL, USA, 2014; pp. 747–750.
75. Bruinenberg, P.; Serisier, D.; Cipolla, D.; Blanchard, J. Safety, Tolerability, Pharmacokinetics and Antimicrobial Activity of Inhaled Liposomal Ciprofloxacin Formulations in Humans. North American Cystic Fibrosis Conference. Pediatr. Pulmonol. 2010, 45 (S33), 354.
76. Bruinenberg, P.; Blanchard, J.; Cipolla, D.; Serisier, D. Safety, Tolerability and Pharmacokinetics of Novel Liposomal Ciprofloxacin Formulations for Inhalation in Healthy Volunteers and in Non-Cystic Bronchiectasis Patients. ATS International Conference 2010. [CrossRef]
77. Aradigm press release on 13 October 2015. Available online: http://investor.aradigm.com/releasedetail.cfm? ReleaseID=936283 (accessed on 18 February 2016).
78. Cipolla, D.; Chan, H.-K.; Schuster, J.; Farina, D. Personalized Medicine: Development of Inhalation Systems Tailored to the Individual. Ther. Deliv. 2010, 1, 667–682. [CrossRef][PubMed]
79. Cipolla, D.; Wu, H.; Eastman, S.; Redelmeier, T.; Gonda, I.; Chan, H.-K. Modifying the Release Properties of Liposomes toward Personalized Medicine. J. Pharm. Sci. 2014, 103, 1851–1862. [CrossRef][PubMed]
80. Cipolla, D.; Wu, H.; Salentenig, S.; Boyd, B.; Rades, T.; Vanhecke, D.; Petri-Fink, A.; Rothen-Rutishauser, B.; Eastman, S.; Redelmeier, T. et al. Formation of Drug Nanocrystals under Nanoconfinement Afforded by Liposomes. RSC Adv. 2016, 6, 6223–6233. [CrossRef]
81. Cipolla, D.; Wu, H.; Gonda, I.; Chan, H.-K. Aerosol performance and long term stability of surfactant-associated liposomal ciprofloxacin formulations with modified encapsulation and release properties. AAPS PharmSciTech. 2014, 15, 1218–1227. [CrossRef][PubMed]
82. Cipolla, D.; Wu, H.; Gonda, I.; Chan, H.-K. Aerosol Performance and Stability of Liposomes Containing Ciprofloxacin Nanocrystals. J. Aer. Med. Pulm. Drug Deliv. 2015, 28, 411–422. [CrossRef][PubMed]
83. Schreier, H. Liposome Aerosols. J. Liposome Res. 1992, 2, 145–184. [CrossRef]